Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Operating Expenses (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Operating Expenses for 14 consecutive years, with $36.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses fell 43.26% year-over-year to $36.1 million, compared with a TTM value of $154.4 million through Dec 2025, down 31.07%, and an annual FY2025 reading of $154.4 million, down 31.07% over the prior year.
  • Operating Expenses was $36.1 million for Q4 2025 at Fate Therapeutics, down from $36.5 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $108.8 million in Q4 2022 and bottomed at $36.1 million in Q4 2025.
  • Average Operating Expenses over 5 years is $65.5 million, with a median of $58.8 million recorded in 2021.
  • The sharpest move saw Operating Expenses skyrocketed 76.32% in 2021, then crashed 54.26% in 2023.
  • Year by year, Operating Expenses stood at $86.5 million in 2021, then increased by 25.82% to $108.8 million in 2022, then plummeted by 54.26% to $49.8 million in 2023, then rose by 27.85% to $63.6 million in 2024, then crashed by 43.26% to $36.1 million in 2025.
  • Business Quant data shows Operating Expenses for FATE at $36.1 million in Q4 2025, $36.5 million in Q3 2025, and $38.9 million in Q2 2025.